Table 2.
Personal and laboratory findings of 64 cases of with influenza in the good and poor prognosis groups
| Group A (n = 47) | Group B (n = 17) | P | |
|---|---|---|---|
| Age (year) | 56 (50–67) | 58 (44–66) | 0.593 |
| Sex (male) | 29 (61.70%) | 12 (70.59%) | 0.513 |
| Length of stay in hospital(d) | 14 (7–18) | 26 (18.5–36) | < 0.001*** |
| Underlying disease | |||
| Hypertension | 17 (36.17%) | 5 (29.41%) | 0.615 |
| Diabetes | 7 (14.89%) | 4 (23.53%) | 0.665 |
| Liver diseases | 10 (21.28%) | 1 (5.88%) | 0.286 |
| Cardiovascular diseases | 5 (10.64%) | 3 (17.65%) | 0.748 |
| Respiratory diseases | 3 (6.38%) | 2 (11.76%) | 0.856 |
| Kidney diseases | 7 (14.89%) | 4 (23.53%) | 0.665 |
| Tumor | 10 (21.28%) | 8 (47.06%) | 0.087 |
| Cerebrovascular diseases | 3 (6.38%) | 3 (17.65%) | 0.379 |
| Symptom | |||
| Cough | 38 (80.85%) | 12 (70.59%) | 0.593 |
| Sore throat | 3 (6.38%) | 0 (0%) | 0.691 |
| Diarrhea | 2 (4.26%) | 1 (5.88%) | 1.000 |
| Dyspnea | 10 (21.28%) | 9 (52.94%) | 0.014* |
| Chill | 7 (14.89%) | 0 (0%) | 0.218 |
| Runny nose | 3 (6.38%) | 0 (0%) | 0.691 |
| Muscle soreness | 4 (8.51%) | 0 (0%) | 0.511 |
| Viral subtypes | |||
| Influenza A(Undifferentiated) | 40 (85.11%) | 16 (94.12%) | 0.593 |
| Influenza B | 7 (14.89%) | 1 (5.88%) | 0.593 |
| Mixed infection | 4 (8.51%) | 10 (58.82%) | < 0.001*** |
| Pneumonia subtype | |||
| Mixed viral and bacterial | 3 (6.38%) | 5 (29.41%) | 0.042* |
| Primary viral | 44 (93.61%) | 12 (70.58%) | 0.042* |
| Laboratory indicators | |||
| WBC (× 109 L−1) | 5.7 (4.3–7.4) | 8.1 (3.3–14.1) | 0.130 |
| Neutrophil ratio (%) | 75.2 (62.7–85.7) | 86.9 (79.8–93.65) | 0.003*** |
| Lymphocyte ratio (%) | 14.6 (10.3–24.4) | 5.9 (3.65–12.2) | 0.001*** |
| CRP (mg/L) | 26.4 (9.9–88.14) | 96.02 (30.595–192.97) | 0.008** |
| ALT (U/L) | 22 (13.75–40) | 23 (15.50–70) | 0.479 |
| AST (U/L) | 32 (20–55) | 33.5 (25.5–49.5) | 0.794 |
| LDH (U/L) | 271 (219–362.5) | 339.5 (269.5–493.25) | 0.047* |
| CK (U/L) | 55.5 (25.75–231.25) | 75.5 (37.5–151.25) | 0.568 |
| Cr (U/L) | 65 (55–85) | 69 (58.5–83) | 0.627 |
| Total protein level (g/L) | 60.2 (52.3–64.1) | 54.2 (47.8–63.1) | 0.109 |
| Urea nitrogen(mmol/l) | 5.81 (4.19–8.63) | 9.93 (6.48–14.67) | 0.010* |
| Treatment | |||
| Antiviral | 38 (80.85%) | 17 (100%) | 0.052 |
| Antibiotic | 44 (93.62%) | 17 (100%) | 0.691 |
| Glucocorticoid | 22 (46.81%) | 15 (88.24%) | 0.003*** |
| Antifungal | 12 (25.53%) | 12 (70.59%) | 0.001** |
Group A, good prognosis group,patients who did not require ventilator treatment or ECMO, were not admitted to the ICU, and did not die within 90 days. Group B, fatal and serious cases group, patients experienced either ventilator treatment, ECMO, ICU or death
WBC, white blood cell; CRP, C-reactive protein; ALT, alanine aminotransferase; AST, aspartate aminotransferase; CK, creatine kinase; LDH, lactate dehydrogenase; Cr, Creatinine
Significant differences between Group A and Group B are indicated by asterisks
(*: P < 0.05; **: P < 0.01; ***: P < 0.001)